Bionano Genomics (BNGO) EBT Margin (2017 - 2026)

Bionano Genomics has disclosed EBT Margin across 10 years of filings, most recently posting 124.02% for Q1 2026.

• EBT Margin for Q1 2026 came in at 124.02%, down 7608.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 109.7% (up 18568.0% YoY), and the FY2025 annual result was 92.35%, up 27294.0% from the prior year.
• EBT Margin came in at 124.02% for Q1 2026 at Bionano Genomics, down from 99.33% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 47.93% in Q1 2025 to a low of 1207.63% in Q3 2023.
• The 5-year median for EBT Margin is 409.73% (2023), against an average of 382.23%.
• Across the five-year window, EBT Margin slumped 76751 bps in 2023 and surged 61294 bps in 2025, its largest moves.
• Bionano Genomics' EBT Margin stood at 448.84% in 2022, then gained by 9 bps to 409.73% in 2023, then jumped by 39 bps to 251.89% in 2024, then surged by 61 bps to 99.33% in 2025, then decreased by 25 bps to 124.02% in 2026.
• The last three EBT Margin figures came in at 124.02% (Q1 2026), 99.33% (Q4 2025), and 115.23% (Q3 2025), per Business Quant data.